<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Adjunctive treatments for opioid withdrawal symptoms</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Adjunctive treatments for opioid withdrawal symptoms</h1>
<div class="graphic"><div class="figure"><div class="ttl">Adjunctive treatments for opioid withdrawal symptoms</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="20%"></colgroup><colgroup width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Symptoms</td> <td class="subtitle1">Medication</td> <td class="subtitle1">Usual effective dose range (adult)</td> <td class="subtitle1">Notes</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Anxiety</td> </tr> <tr> <td class="indent1" rowspan="6"><strong>Anxiety, irritability, restlessness</strong></td> <td>Diphenhydramine<sup>*</sup></td> <td>50 to 100 mg orally every 4 to 6 hours as needed (maximum 300 mg daily)</td> <td> <ul> <li>May also treat nausea</li> <li>Use reduced dose in hepatic impairment</li> <li>IV and IM administration available</li> </ul> </td> </tr> <tr> <td>Hydroxyzine</td> <td>25 to 100 mg orally every 6 to 8 hours as needed (maximum 400 mg daily)</td> <td> <ul> <li>May also treat lacrimation and rhinorrhea</li> <li>Use reduced dose (50%) in renal or hepatic impairment</li> <li>IM administration available</li> </ul> </td> </tr> <tr> <td>Clonazepam<sup>¶</sup></td> <td>0.5 to 1.5 mg orally every 6 to 8 hours as needed (maximum 6 mg daily)</td> <td> <ul> <li>Use with caution and reduce dose in mild hepatic or renal impairment; active metabolites can accumulate</li> <li>Avoid in moderate to severe hepatic impairment or hepatic encephalopathy</li> </ul> </td> </tr> <tr> <td>Lorazepam<sup>¶</sup></td> <td>1 mg orally every 4 to 6 hours as needed (maximum 6 mg daily)</td> <td> <ul> <li>Relatively safe in mild to moderate hepatic impairment; use of reduced dose may be needed</li> <li>Avoid in severe hepatic impairment or hepatic encephalopathy</li> <li>IV and IM administration available; use caution in renal impairment due to propylene glycol diluent</li> </ul> </td> </tr> <tr> <td>Oxazepam<sup>¶</sup></td> <td>15 to 30 mg orally every 6 to 8 hours as needed (maximum 120 mg daily)</td> <td> <ul> <li>Relatively safe in mild to moderate hepatic or renal impairment</li> <li>Use with caution in severe renal impairment</li> <li>Avoid in severe hepatic impairment or hepatic encephalopathy</li> </ul> </td> </tr> <tr> <td>Buspirone</td> <td>10 to 15 mg every 8 hours as needed (maximum 60 mg daily)</td> <td> <ul> <li>Has delayed action, so start day 1 of withdrawal and continue as long as symptoms of withdrawal persist</li> <li>Not recommended in severe renal or hepatic impairment; in mild to moderate renal or hepatic impairment, dose adjustments are based on signs of side effects (eg, oversedation, dizziness, headache)</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Gastrointestinal</td> </tr> <tr> <td class="indent1"><strong>Abdominal cramping</strong></td> <td>Dicyclomine<sup>*</sup></td> <td>10 to 20 mg orally every 6 to 8 hours as needed (maximum 160 mg daily)</td> <td> <ul> <li>IM administration available (lower doses are used)</li> <li>Use with caution and reduce dose in renal or hepatic impairment</li> </ul> </td> </tr> <tr> <td class="indent1" rowspan="2"><strong>Diarrhea</strong></td> <td>Bismuth<sup>*</sup></td> <td>~524 mg orally every 30 to 60 minutes as needed (up to 4200 mg daily)</td> <td rowspan="2"> <ul> <li>Monitor for dehydration and maintain fluid levels with oral and/or IV hydration</li> </ul> </td> </tr> <tr> <td>Loperamide</td> <td>4 mg orally followed by 2 mg after each loose stool (maximum 16 mg daily)</td> </tr> <tr> <td class="indent1" rowspan="3"><strong>Nausea/vomiting</strong></td> <td>Ondansetron<sup>*Δ</sup></td> <td>4 to 8 mg orally or IV every 12 hours as needed (maximum 16 mg/day)</td> <td> <ul> <li>Monitor for dehydration and maintain fluid levels with oral and/or IV hydration</li> <li>Dose-dependent QT interval prolongation; risk of rare, potentially fatal, ventricular arrhythmia; use with caution (eg, monitor baseline and post-dose electrocardiogram) or avoid in patients with features of elevated risk<sup>Δ</sup></li> <li>Use caution and reduced dose (50%) in severe hepatic impairment</li> </ul> </td> </tr> <tr> <td>Prochlorperazine</td> <td>5 to 10 mg orally three times daily before meals or every six hours as needed (maximum 40 mg/day)</td> <td> <ul> <li>Monitor for dehydration and maintain fluid levels with oral and/or IV hydration</li> <li>Use with caution in mild to moderate hepatic impairment; avoid in severe hepatic impairment</li> <li>IV and rectal administration available</li> </ul> </td> </tr> <tr> <td>Promethazine</td> <td>12.5 to 25 mg orally every 4 to 6 hours as needed (maximum 50 mg/day)</td> <td> <ul> <li>Monitor for dehydration and maintain fluid levels with oral and/or IV hydration</li> <li>Use with caution in mild to moderate hepatic impairment; avoid in severe hepatic impairment</li> <li>IM and rectal administration available (IV use not recommended)</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Insomnia, pain, muscle spasm, and restless legs</td> </tr> <tr> <td class="indent1" rowspan="5"><strong>Insomnia</strong></td> <td>Trazodone<sup>*</sup></td> <td>25 to 100 mg orally at bedtime</td> <td> <ul> <li>May titrate nightly up to 300 mg at bedtime if needed</li> <li>Use with caution in severe hepatic or renal impairment</li> </ul> </td> </tr> <tr> <td>Doxepin</td> <td>6 to 50 mg orally at bedtime</td> <td> <ul> <li>Use with caution and reduce dose in severe hepatic impairment</li> </ul> </td> </tr> <tr> <td>Mirtazapine</td> <td>7.5 to 15 mg orally at bedtime</td> <td> <ul> <li>May need to use lower dose in moderate to severe hepatic or renal impairment</li> </ul> </td> </tr> <tr> <td>Quetiapine</td> <td>50 to 100 mg orally at bedtime</td> <td> <ul> <li>Use lower initial dose (25 mg) in hepatic impairment and adjust based on response</li> </ul> </td> </tr> <tr> <td>Zolpidem<sup>¶</sup></td> <td>5 to 10 mg orally at bedtime</td> <td> <ul> <li>A dose of 5 mg is usually appropriate for female patients and those with mild or moderate hepatic impairment</li> <li>Avoid in severe hepatic impairment or hepatic encephalopathy</li> </ul> </td> </tr> <tr> <td class="indent1" rowspan="4"><strong>Muscle aches</strong><sup>◊</sup><strong>, joint pain, headache</strong></td> <td>Ibuprofen<sup>*§</sup></td> <td>400 mg orally every 4 to 6 hours as needed (maximum 2400 mg daily)</td> <td> <ul> <li>Patient should be well hydrated and without significant kidney disease</li> <li>Use with caution in mild to moderate hepatic or renal impairment</li> <li>Avoid all NSAIDs in severe renal or hepatic impairment or cirrhosis</li> </ul> </td> </tr> <tr> <td>Acetaminophen</td> <td>650 to 1000 mg orally every 4 to 6 hours as needed (maximum 4000 mg daily)</td> <td> <ul> <li>Appropriate analgesic for most patients</li> <li>Use reduced dose (ie, 2000 mg daily) or avoid in hepatic impairment or if malnourished</li> </ul> </td> </tr> <tr> <td>Ketorolac<sup>§</sup></td> <td>15 to 30 mg IV or IM every 6 hours as needed (maximum 120 mg daily)</td> <td> <ul> <li>Patient should be well hydrated and without significant kidney disease</li> <li>Limit use to 5 days or less</li> <li>Use with caution and reduce dose (50%) in older adults (ie, ≥65 years), patients &lt;50 kg, and patients with mild to moderate renal impairment</li> <li>Use with caution in mild to moderate hepatic impairment</li> <li>Contraindicated in severe renal or hepatic impairment or volume depletion</li> </ul> </td> </tr> <tr> <td>Naproxen<sup>§</sup></td> <td>500 mg orally twice daily with meals</td> <td> <ul> <li>Patient should be well hydrated and without significant kidney disease</li> <li>Use with caution in mild to moderate hepatic or renal impairment</li> <li>Avoid all NSAIDs in severe renal or hepatic impairment or cirrhosis</li> </ul> </td> </tr> <tr> <td class="indent1" rowspan="4"><strong>Muscle spasm</strong><sup>◊</sup><strong>, restless legs</strong></td> <td>Cyclobenzaprine<sup>*</sup></td> <td>5 to 10 mg orally every 8 hours as needed (maximum 30 mg daily)</td> <td> <ul> <li>Use reduced dose in mild hepatic impairment</li> <li>Avoid in moderate to severe haptic impairment</li> </ul> </td> </tr> <tr> <td>Baclofen</td> <td>5 to 10 mg orally every 8 hours as needed (maximum 60 mg daily)</td> <td> <ul> <li>Use reduced dose in renal impairment</li> </ul> </td> </tr> <tr> <td>Diazepam<sup>¶</sup></td> <td>5 to 10 mg orally every 6 to 12 hours as needed (maximum 40 mg daily)</td> <td> <ul> <li>Use with caution in hepatic or renal impairment</li> <li>Avoid in severe hepatic impairment or hepatic encephalopathy</li> <li>IM and IV administration available</li> </ul> </td> </tr> <tr> <td>Methocarbamol</td> <td>750 to 1500 mg orally every 8 hours as needed (maximum 6 g daily)</td> <td> <ul> <li>Use with caution in hepatic or renal impairment</li> <li>IM and IV administration available (lower doses are used); avoid parenteral formulation in renal impairment (propylene glycol additive)</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd"><ul>
<li>A calm, quiet environment with supportive and reassuring staff can be instrumental for helping patients overcome most symptoms of acute opioid withdrawal and decreases the need for pharmacologic interventions.</li>
<li>Patients who have diarrhea, vomiting, or sweating should be monitored for dehydration and fluid levels maintained with oral and/or intravenous fluids.</li>
<li>The role of opioid replacement therapies and alpha-2 agonists (eg, clonidine) in management of acute opioid withdrawal and maintenance pharmacotherapy in opioid use disorder is discussed separately; refer to accompanying text.</li>
<li>This is not a complete list of cautionary information or dose adjustments in organ impairment. For additional information refer to the Lexicomp drug monographs included within UpToDate.</li>
</ul></div><div class="graphic_footnotes"><p>IM: intramuscular; IV: intravenous; NSAID: nonsteroidal anti-inflammatory drug.</p>
<p>* Author's first choice.</p>
<p>¶ Use of benzodiazepines and benzodiazepine agonists (eg, zolpidem) is NOT recommended in patients receiving methadone or buprenorphine therapy unless under close medical supervision. Patients who resume heroin (diamorphine) use after a period of abstinence are at high risk of fatally overdosing, particularly if heroin use is resumed in combination with benzodiazepines, alcohol, or other drugs with sedative characteristics (eg, quetiapine). The use of benzodiazepines should be limited to 5 to 10 days in total and tapered. They are not recommended for use in supervised outpatient withdrawal and should be reserved for inpatient settings where frequent clinical monitoring is provided.</p>
<p>Δ Risk of QTc prolongation or torsades de pointes is also elevated with advanced age, female sex, heart disease, congenital long QT syndrome, hypokalemia or hypomagnesemia, overly rapid IV administration, and combination of drugs with QTc prolonging effects (eg, methadone). Refer to topic on acquired long QT syndrome.</p>
<p>◊ Warm baths, rehydration, and gentle stretching are also helpful for relieving muscle aches and cramps.</p>
§ Safety concerns of NSAID use in older adults and patients with, or at elevated risk for, cardiovascular disease, gastrointestinal bleeding, organ dysfunction, or thrombotic events are addressed separately in UpToDate.</div><div class="graphic_reference">Prepared with data from Lexicomp Online. Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved.</div><div id="graphicVersion">Graphic 106793 Version 13.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
